Superworth

Nexalin Technology price to sales ratio NXL

Market value divided by revenue over the last twelve months, since 2024.

Today, Nov 2, 2026
5.1×
3-year median
67.7×
Against its 3-year history
0th
percentile: 0 is its lowest day, 100 its highest
3-year range
5.1× to 189×
Peer median
1.7×

Nexalin Technology's price to sales ratio is 5.1× as of Nov 2, 2026.

That is below its 3-year median of 67.7×, lower than on 100% of days in the last 3 years.

Over that time it ranged from 5.1× in Nov 2026 to 189× in Mar 2025.

The median for 10 medical device stocks of a similar size is 1.7×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.1×5.1×84.7×
202574.9×74.9×189×
2024161×32.8×167×

Against its peers

Companies in Medical - Devices nearest Nexalin Technology's size, closest first, today.

CompanyPrice to sales ratio
NXLNexalin Technology5.1×
NUWENuwellis0.2×
NDRAENDRA Life Sciencesn/m
IRIXIridex0.2×
QTIQT Imaging1.2×
POCIPrecision Optics1.7×
ECORelectroCore1.7×
OMOutset Medical0.6×
HYPRHyperfine4.6×
NRXSNeuraxis, INC15.6×
STXSStereotaxis2.9×
Peer median1.7×

Where Nexalin Technology ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Nexalin Technology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.